Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for OncoCyte Corporation (OCX : NSDQ)
 
 • Company Description   
OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.

Number of Employees: 110

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.14 Daily Weekly Monthly
20 Day Moving Average: 595,426 shares
Shares Outstanding: 99.94 (millions)
Market Capitalization: $113.93 (millions)
Beta: 1.87
52 Week High: $6.25
52 Week Low: $1.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.00% 7.97%
12 Week -13.64% -6.99%
Year To Date -47.47% -36.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15 CUSHING
-
IRVINE,CA 92618
USA
ph: 949-409-7600
fax: 510-521-3389
bob@lifesciadvisors.com http://www.oncocyte.com
 
 • General Corporate Information   
Officers
Ronald Andrews - President and Chief Executive Officer
Li Yu - Vice President and Controller
Mitchell Levine - Chief Financial Officer
Melinda Griffith - Director
Andrew Arno - Director

Peer Information
OncoCyte Corporation (CHCR)
OncoCyte Corporation (ESRX)
OncoCyte Corporation (MYDP)
OncoCyte Corporation (GBCS)
OncoCyte Corporation (LAXAF)
OncoCyte Corporation (IPCM)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Medical Services
Sector: Medical
CUSIP: 68235C107
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 99.94
Most Recent Split Date: (:1)
Beta: 1.87
Market Capitalization: $113.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.52 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.00
Price/Cash Flow: -
Price / Sales: 14.19
EPS Growth
vs. Year Ago Period: -175.00%
vs. Previous Quarter: 8.33%
Sales Growth
vs. Year Ago Period: 26.78%
vs. Previous Quarter: -60.30%
ROE
03/31/22 - -52.12
12/31/21 - -37.25
09/30/21 - -35.36
ROA
03/31/22 - -25.93
12/31/21 - -21.94
09/30/21 - -22.81
Current Ratio
03/31/22 - 1.76
12/31/21 - 2.77
09/30/21 - 3.56
Quick Ratio
03/31/22 - 1.76
12/31/21 - 2.77
09/30/21 - 3.56
Operating Margin
03/31/22 - -526.22
12/31/21 - -450.52
09/30/21 - -651.63
Net Margin
03/31/22 - -877.80
12/31/21 - -829.52
09/30/21 - -743.83
Pre-Tax Margin
03/31/22 - -898.93
12/31/21 - -949.37
09/30/21 - -948.89
Book Value
03/31/22 - 0.57
12/31/21 - 0.71
09/30/21 - 1.08
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.18
 

Powered by Zacks Investment Research ©